ATE286720T1 - Pharmazeutische formulierungen auf basis fester dispersionen - Google Patents

Pharmazeutische formulierungen auf basis fester dispersionen

Info

Publication number
ATE286720T1
ATE286720T1 AT00977140T AT00977140T ATE286720T1 AT E286720 T1 ATE286720 T1 AT E286720T1 AT 00977140 T AT00977140 T AT 00977140T AT 00977140 T AT00977140 T AT 00977140T AT E286720 T1 ATE286720 T1 AT E286720T1
Authority
AT
Austria
Prior art keywords
solid dispersion
pharmaceutical formulations
solid dispersions
formulations based
disclosed
Prior art date
Application number
AT00977140T
Other languages
English (en)
Inventor
James J Fort
Steven L Krill
Devalina Law
Yihong Qiu
William R Porter
Eric A Schmitt
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23745019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE286720(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE286720T1 publication Critical patent/ATE286720T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00977140T 1999-11-12 2000-11-10 Pharmazeutische formulierungen auf basis fester dispersionen ATE286720T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43951499A 1999-11-12 1999-11-12
PCT/US2000/030910 WO2001034118A2 (en) 1999-11-12 2000-11-10 Solid dispersion pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ATE286720T1 true ATE286720T1 (de) 2005-01-15

Family

ID=23745019

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00977140T ATE286720T1 (de) 1999-11-12 2000-11-10 Pharmazeutische formulierungen auf basis fester dispersionen

Country Status (10)

Country Link
EP (1) EP1227797B1 (de)
JP (1) JP4815085B2 (de)
AT (1) ATE286720T1 (de)
CA (1) CA2390092C (de)
DE (1) DE60017444T2 (de)
DK (1) DK1227797T3 (de)
ES (1) ES2235991T3 (de)
MX (1) MXPA02004739A (de)
PT (1) PT1227797E (de)
WO (1) WO2001034118A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
WO2001034119A2 (en) 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
PT1390063E (pt) * 2001-05-03 2005-03-31 Hoffmann La Roche Forma de dosagem farmaceutica de mesilato de nelfinavir amorfo
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8974823B2 (en) 2003-12-31 2015-03-10 Bend Research, Inc. Solid compositions of low-solubility drugs and poloxamers
KR100954828B1 (ko) 2006-12-22 2010-04-27 주식회사유한양행 레바프라잔 함유 고체분산체 및 그의 제조방법
JP5593013B2 (ja) * 2007-04-20 2014-09-17 株式会社感光社 固体型殺菌剤及び人体施用組成物
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
WO2012164575A2 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
EP3569225A1 (de) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Feste dispersion mit ritonavir

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
DE60017444D1 (de) 2005-02-17
PT1227797E (pt) 2005-05-31
WO2001034118A2 (en) 2001-05-17
ES2235991T3 (es) 2005-07-16
CA2390092C (en) 2009-07-14
CA2390092A1 (en) 2001-05-17
JP2003530310A (ja) 2003-10-14
MXPA02004739A (es) 2003-01-28
EP1227797A2 (de) 2002-08-07
EP1227797B1 (de) 2005-01-12
JP4815085B2 (ja) 2011-11-16
DK1227797T3 (da) 2005-05-30
DE60017444T2 (de) 2006-02-09
WO2001034118A3 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
ATE329579T1 (de) Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE60017444D1 (de) Pharmazeutische formulierungen auf basis fester dispersionen
DE60121570D1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
MX358033B (es) Forma de dosificación farmacéutica sólida que comprende al menos un inhibidor de proteasa de hiv.
CA2322315A1 (en) Fast disintegrating tablets
AR020610A1 (es) Utilizacion de un copolimero de acido metacrilico de tipo c segun la farmacopea us national formulary usp/nf, como agente de desagregacion y el procedimiento de fabricaion de un comprimido con dicho copolimero
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
DE60237449D1 (de) Ammensetzungen und damit in beziehung stehende verwendungen
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
AR024384A1 (es) UNA FORMA DE DOSIFICACIoN FARMACÉUTICA DE DISOLUCIoN INSTANTÁNEA Y UN MÉTODO PARA PREPARARLA
BG103425A (en) Pharmaceutical composition
MY127908A (en) Improved pharmaceutical formulations.
PT1083884E (pt) Processo para a estabilizacao de composicoes de polivinil-pirrolidona
WO2000040205A3 (en) Sustained release formulation with reduced moisture sensitivity
IT1256386B (it) Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo
SE0004671D0 (sv) Pharmaceutical formulation
CY1108863T1 (el) Φαρμακευτικο σκευασμα εκτεταμενης απελευθερωσης ανεξαρτητης απο το ρη
WO2001089317A3 (en) Dietary aids and methods of use thereof
GEP20033078B (en) Controlled-Release Compositions of Betahistine
PT1263413E (pt) Metodo de preparacao de dispersoes solidas
SE0001916D0 (sv) Novel formulation
ES2171089T3 (es) Soluciones salinas hipoosmoticas, su procedimiento de preparacion y medicamentos a base de estas soluciones.
AU2001284189A1 (en) Modified release formulation
WO2004096155A3 (en) Tablets and methods for modified release of hydrophilic and other active agents
ATE300293T1 (de) Pharmazeutische zusammensetzungen, die schwerlösliche arzneistoffe enthalten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1227797

Country of ref document: EP